Logo

Decode Buys Cancer Research Firm UVS for $5.5M in Stock

Jan 18, 2006

NEW YORK, Jan. 18 (GenomeWeb News) - Decode Genetics has bought Urdur, Verdandi, Skuld, a privately held Icelandic cancer research company, to expand its discovery and drug development capabilities based on population genetics, Decode said today.

 

"UVS has organized cancer research in Iceland since 1998 and has recruited a large number of patients and controls into their studies," said Decode's CEO, Kari Stefansson, in a statement.

 

Reykjavik-based Decode acquired UVS for $5.5 million in common stock based on the average closing price for the 30 days preceding the acquisition, according to the statement.

 

Shares of Decode were trading lower in afternoon trade, after hitting a 52-week high yesterday of $10.77.

Breaking News
The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.